Biotechnik

CeGaT Acquires Two Additional NovaSeq 6000 High-Throughput Sequencing Systems

CeGaT, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, is investing in new NovaSeq 6000 sequencing systems from Illumina. This acquisition is a strategically important move given CeGaT’s rapid corporate growth.

CeGaT has acquired a sixth and seventh NovaSeq 6000 to meet the increasing demand for sequencing and genetic analysis in the future. These sequencers are Illumina’s most powerful next-generation sequencing platforms. They can be used, for example, to analyze genomes, meaning the entire genetic information of an individual, in the shortest possible time. With a total of seven instruments, CeGaT can generate data volumes of up to 42 terabytes in less than two days. CeGaT continuously invests in state-of-the-art equipment and can thus offer its international customers short analysis times and a steadily growing portfolio of sequencing services.

Largest owner-managed sequencing service provider in Europe

Dr. Jiri Ködding, Director Operations at CeGaT, is proud of the development: "We already acquired our fourth and fifth NovaSeq 6000 two years ago. This has enabled us to sequence 9,000 to 14,000 additional genomes per year. Fortunately, the demand for our sequencing services is increasing so strongly that we are again reaching capacity limits. Our ambition is and remains to make next-generation sequencing accessible to all research groups. To this end, we are now creating further capacity, making us the largest privately managed sequencing provider in Europe."

Millions invested in the Tübingen Technology Park

The investments in the future are not limited to high-throughput sequencers. CeGaT has been constructing an annex building since 2021, for which 20 to 25 million euros have been budgeted. Completion is expected in 2023. Additional laboratory and office space will be built on three floors to provide space for 400 to 500 employees. It was only in 2014 that CeGaT moved from rented premises to its own newly built company building in Tübingen, Paul-Ehrlich-Strasse.

Über die CeGaT GmbH

CeGaT GmbH, founded in Tübingen, Germany, in 2009, is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations, driving science forward with own findings. The owner-managed company stands for independence, extensive personal customer service, and premium quality. CeGaT’s laboratory is accredited according to CAP/CLIA and DIN EN ISO 15189, hence meeting the highest international standards. To keep the responsibility for the whole project, and to maintain the best results, CeGaT carries out all steps in-house and under scientific supervision.

Firmenkontakt und Herausgeber der Meldung:

CeGaT GmbH
Paul-Ehrlich-Str. 23
72076 Tübingen
Telefon: +49 7071 56544 260
http://www.cegat.com

Ansprechpartner:
Christfried Dornis
Marketing & Communication
Telefon: +49 (7071) 56544-260
E-Mail: christfried.dornis@cegat.de
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel